2023 年度履职情况评估报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，江苏 亚虹医药科技股份有限公司（以下简称"公司"）聘请立信会计师事务所（特殊 普通合伙）（以下简称"立信"）担任公司 2023 年度审计机构。根据财政部、国 资委及中国证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》，公司对立信在近一年审计中的履职情况进行了评估。经评估，公 司认为，近一年立信资质等方面合规有效，履职能够保持独立性，勤勉尽责、 公允表达意见。具体情况如下： 一、会计师事务所基本情况 江苏亚虹医药科技股份有限公司 关于立信会计师事务所（特殊普通合伙） （一）基本情况 立信由潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国 首家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙 人为朱建弟先生。立信是国际会计网络 BDO 的成员所，长期从事证券服务业务， 新证券法实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美国 公众公司会计监督委员会（PCAOB）注册登 ...

本人作为江苏亚虹医药科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《江苏亚虹医药科技股 份有限公司章程》（以下简称"《公司章程》"）、《上市公司独立董事管理办法》的 有关规定，本着对公司及全体股东负责的态度，以关注和维护全体股东特别是中 小股东利益为宗旨，2023 年度，本人诚信、勤勉地履行独立董事的职责，对各项 议案进行认真审议，积极参与公司决策，为公司治理结构的完善和规范运作起到 了积极作用。现将具体工作情况汇报如下： 江苏亚虹医药科技股份有限公司 2023 年度独立董事述职报告 一、独立董事的基本情况 （一）独立董事人员情况 公司第一届董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数三分 之一以上，符合相关法律法规及公司制度的规定。 公司于 2023 年 12 月 28 日完成换届选举工作，第二届董事会由 9 名董事组 成，其中独立董事 3 名，占董事会人数三分之一以上，符合相关法律法规及公司 制度的规定。 （二）个人工作履历、专业背景以及兼职情况 黄彬，1967 年生，中国国籍，无境外永久居留权。黄彬先生于北京师范大学 取得学士学 ...

江苏亚虹医药科技股份有限公司 内部控制审计报告 2023 年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ . 立信会计师事务所(特殊普通合伙) HINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTAN 内部控制审计报告 信会师报字[2024]第 ZA11210 号 江苏亚虹医药科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了江苏亚虹医药科技股份有限公司(以下简称"贵 公司")2023年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是贵公司董事会的责任。 立信会计师事务所(特殊普通合伙) O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 四、财务报告内部控制审计意见 我们认为,贵公司按照《企业内部控制基本规范》和相关规定在 所有重大方面保持了有效的财务报告内部控制。 ...

一、监事会会议召开情况 江苏亚虹医药科技股份有限公司（以下简称"公司"）第二届监事会第三次 会议通知于 2024 年 4 月 7 日以邮件等方式送达全体监事，会议于 2024 年 4 月 17 日在公司会议室以现场参会方式召开。本次会议由监事会主席钟毅先生召集 并主持，应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%；本次 会议的召集和召开程序符合《中华人民共和国公司法》等法律法规、规范性文件 以及《江苏亚虹医药科技股份有限公司章程》（以下简称"《公司章程》"）的 相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 证券代码：688176 证券简称：亚虹医药 公告编号：2024-025 江苏亚虹医药科技股份有限公司 第二届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）审议通过《关于公司<2023 年年度报告>及其摘要的议案》 经审议，监事会认为：公司编制和审核公司《2023 年年度报告》及其摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 ...

公司本次发行募集资金已于 2021 年 12 月 31 日全部到位，立信会计师事务 所（特殊普通合伙）于 2021 年 12 月 31 日出具了信会师报字[2021]第 ZA15998 号《验资报告》，对本次发行募集资金的到位情况进行了验证。 中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 2023 年度募集资金存放与实际使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"亚虹医药"或"公司"）首次公开发行的 保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》《科 创板上市公司持续监管办法（试行）》等有关规定，对亚虹医药 2023 年度募集资 金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到位情况 经中国证券监督管理委员会作出《关于同意江苏亚虹医药科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021 ...

2023 年度独立董事述职报告 本人作为江苏亚虹医药科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《江苏亚虹医药科技股 份有限公司章程》（以下简称"《公司章程》"）、《上市公司独立董事管理办法》的 有关规定，本着对公司及全体股东负责的态度，以关注和维护全体股东特别是中 小股东利益为宗旨，2023 年度，本人诚信、勤勉地履行独立董事的职责，认真审 议各项议案，对重大事项发表了独立意见，充分发挥独立董事的作用，维护了公 司和股东特别是中小股东的利益。报告期内，因第一届董事会届满，换届后本人 离任公司独立董事及董事会审计委员会委员、战略与投资委员会委员、提名委员 会委员主任委员职务，并不再担任公司任何职务。现就本人 2023 年具体工作情 况汇报如下： 一、独立董事的基本情况 （一）独立董事人员情况 公司第一届董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数三分 之一以上，符合相关法律法规及公司制度的规定。 江苏亚虹医药科技股份有限公司 公司于 2023 年 12 月 28 日完成换届选举工作，换届后本人不再担任公司独 立董事，也不在公司担任任 ...

对外担保管理制度 第一章 总 则 第一条 为规范江苏亚虹医药科技股份有限公司（以下简称"公司"）对外担 保行为，有效防范公司对外担保风险，现根据《中华人民共和国公司 法》《中华人民共和国证券法》《中华人民共和国民法典》等相关法 律、行政法规和规范性文件以及《江苏亚虹医药科技股份有限公司章 程》（以下简称"《公司章程》"），并参照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》等中国证监会及 证券交易所的相关规定，特制定本制度。 第二章 担保原则 1 第二条 本制度所称对外担保，是指公司以第三人的身份为债务人（包括公司 的子公司）对于债权人所负的债务提供担保，当债务人不履行债务时， 由公司按照约定履行债务或承担责任的行为。 第三条 本制度所称的子公司是指公司对其拥有实际控制权的控股子公司或 全资子公司。 第四条 以公司本部或子公司名义进行的所有担保，均由公司统一管理，未按 照《公司章程》的规定经由公司董事会或股东大会批准，公司不得对 外提供担保。 第五条 除《公司章程》和本制度规定之外，公司不得以本公司资产为本公司 的股东或其控制的企业的债务提供担保。 第六条 公司对外担保应当遵循合法、审 ...

江苏亚虹医药科技股份有限公司 2024年度"提质增效重回报"行动方案 投资者是市场之本，是资本市场发展的源头活水。上市公司是市场之基， 通过进一步完善治理、信息透明，更加专注主业、优化资源配置，更加稳健经 营，更好回报投资者，是上市公司应尽的责任与义务。为践行"以投资者为本" 的上市公司发展理念，维护江苏亚虹医药科技股份有限公司（以下简称"公司"） 全体股东利益，基于对公司未来发展前景的信心、对公司价值的认可和切实履 行社会责任，公司特制定 2024 年度"提质增效重回报"行动方案，以进一步提 高运营效率、管理水平，不断提高公司核心竞争力，加强投资者关系管理，保 障投资者权益，维护公司股价稳定，树立良好的市场形象。主要措施如下： 一、推进研发和商业化，提高核心竞争力 公司是专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化专科创新药 公司。秉承"改善人类健康，让生命更有尊严"的企业使命，公司立志成为在 专注治疗领域集研发、生产和商业化为一体的国际领先制药企业，为中国和全 球患者提供最佳的诊疗一体化解决方案。 公司坚持以创新技术和产品为核心驱动力，通过内部完善的研发体系、核 心技术平台和全球药物开发经验专长，深入 ...

中文全称：江苏亚虹医药科技股份有限公司 英文全称：JIANGSU YAHONG MEDITECH CO., LTD. 江苏亚虹医药科技股份有限公司 章 程 二零二四年四月 | 第一章 | 总 | 则 1 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 2 | | 第一节 | | 股份发行 2 | | 第二节 | | 股份增减和回购 8 | | 第三节 | | 股份转让 9 | | 第四章 | | 股东和股东大会 10 | | 第一节 | | 股 东 10 | | 第二节 | | 股东大会的一般规定 13 | | 第三节 | | 股东大会的召集 16 | | 第四节 | | 股东大会的提案与通知 18 | | 第五节 | | 股东大会的召开 19 | | 第六节 | | 股东大会的表决和决议 23 | | 第五章 | | 董事会 28 | | 第一节 | | 董 事 28 | | 第二节 | | 董事会 32 | | 第六章 | | 高级管理人员 38 | | 第七章 | | 监事会 41 | | 第一节 | | 监 事 41 | | 第二节 ...

Stock Incentive Plan - The company implemented a restricted stock incentive plan in 2022, granting a total of 9,790,800 shares, accounting for 1.72% of the total shares, to 151 employees, representing 38.32% of the total workforce[4] - In 2023, the company granted an additional 1,925,000 restricted shares to 18 employees at a price of 6.79 RMB per share, with 4.22 million shares remaining unallocated and automatically expired[5][8] - The total share-based payment expense recognized in the reporting period for the 2022 restricted stock incentive plan was 16,400,970.53 RMB[9] - Key executives and core technical personnel, including the Chairman and CEO, were granted restricted shares, with the Chairman receiving 1.3 million shares and other executives receiving between 22,500 to 130,000 shares each[12] Financial Performance - Revenue for 2023 reached 13,753,343.12 yuan, a significant increase compared to 2022's 26,095.32 yuan[18] - Net profit attributable to shareholders in 2023 was -400,434,603.65 yuan, a decrease from -246,549,785.26 yuan in 2022[18] - Operating cash flow for 2023 was -398,186,688.82 yuan, down from -241,960,907.88 yuan in 2022[18] - Total assets at the end of 2023 were 2,632,270,467.20 yuan, a decrease of 8.41% compared to 2022[18] - Basic earnings per share for 2023 were -0.70 yuan, compared to -0.43 yuan in 2022[19] - Weighted average return on equity for 2023 was -15.52%, down from -8.52% in 2022[19] - Revenue in Q4 2023 was 10,757,271.87 yuan, the highest among all quarters[23] - Net profit attributable to shareholders in Q4 2023 was -132,390,991.55 yuan, the lowest among all quarters[23] - Government subsidies in 2023 amounted to 6,953,033.26 yuan, an increase from 5,929,193.05 yuan in 2022[24] - Non-recurring gains and losses in 2023 totaled 31,788,811.50 yuan, a decrease from 63,493,965.12 yuan in 2022[27] Asset and Investment Changes - The company's trading financial assets decreased by 1,108,968,660.80 RMB, from 1,703,276,190.24 RMB to 594,307,529.44 RMB, impacting the current profit by 23,932,781.55 RMB[31] - The company's other current assets increased by 14,544,364.54 RMB, impacting the current profit by 1,459,111.24 RMB[31] - The company's other equity instrument investments increased by 805,424.10 RMB, from 15,336,049.20 RMB to 16,141,473.30 RMB[31] Product Development and Clinical Trials - The company has 2 marketed products and 13 products in clinical and preclinical development, including 6 in clinical development, with APL-1702 and APL-1202 being global first-in-class drugs[38] - The company's APL-1202, in combination with tislelizumab, showed a significant increase in histological response rate in a Phase II clinical trial for muscle-invasive bladder cancer[35] - The company is preparing to submit an NDA for APL-1702 to the NMPA and is discussing a Phase III clinical trial plan with the FDA for the US market[35] - APL-1202 combined with chemotherapy for recurrent NMIBC did not meet the primary endpoint in the ACCRUE study, leading to the termination of further development in this indication[75] - In the ASCERTAIN study, APL-1202 monotherapy showed similar non-recurrence rates compared to chemotherapy in untreated intermediate-risk NMIBC patients, with 8 out of 21 patients completing over 1 year of treatment[78] - APL-1202 combined with Tislelizumab in the ANTICIPATE study showed a pCR rate of 39% vs 21% for Tislelizumab alone, with promising efficacy signals in MIBC patients[79] - The ANTICIPATE study is expected to release top-line Phase II data in Q3 2024, with plans to prioritize clinical development in China for advanced bladder cancer[80] - APL-1501, a second-generation product of APL-1202, is undergoing Phase I trials in Australia, aiming to improve efficacy and reduce side effects with better pharmacokinetic properties[83] - The company plans to initiate clinical studies in the US for APL-1501 combined with immune checkpoint inhibitors for BCG-unresponsive NMIBC patients, with discussions with FDA planned for 2024[83] - APL-1202 combined with immune checkpoint inhibitors is expected to improve the efficacy of advanced bladder cancer patients, with a current single-agent ORR of only around 25%[84] - APL-1706, a diagnostic imaging agent for bladder cancer, has been approved in over 30 countries and completed Phase III clinical trials in China, showing a 43.3% additional detection rate of bladder cancer lesions compared to standard white light cystoscopy[85] - APL-1706's Phase III clinical trial demonstrated an additional detection rate of ≥1 CIS lesion in 9.6% of subjects, with real-world studies showing a 7.1% additional detection rate[85] - APL-1706's New Drug Application (NDA) was accepted by the National Medical Products Administration in November 2023, with expected approval by June 2025[88] - APL-1702 showed a significant improvement in response rate by 89.4% compared to placebo (41.1% vs. 21.7%, p = 0.0001) in its Phase III clinical trial[90] - APL-1702 demonstrated a 41.4% improvement in HPV clearance rate in the mITT population (28.0% vs. 19.8%) and a 103.9% improvement for high-risk HPV16 and/or HPV18 (31.4% vs. 15.4%)[90] - APL-1702's Phase III clinical trial results were selected for oral presentations at the 2024 EUROGIN and SGO conferences[91] - APL-1702 Phase III clinical trial enrolled 402 patients from multiple countries including China, Germany, and the Netherlands[120] - The trial evaluates the efficacy and safety of APL-1702 for HSIL, with primary endpoint being response rate at 6 months post-treatment[120] - Response rate and HPV16+/HPV18+ clearance rate were compared between APL-1702 and placebo groups[121] - APL-1702 is expected to redefine the treatment goals for cervical precancerous lesions, shifting focus from one-time surgical outcomes to long-term disease management, aiming to balance treatment risks and benefits while avoiding or delaying invasive surgeries[123] - The company plans to submit a pre-submission communication to the European Medicines Agency (EMA) for APL-1702 in Q3 2024 and aims to discuss registration clinical trial designs with the US FDA for the North American market in 2024[123] - APL-1401, a novel oral drug for ulcerative colitis (UC), is undergoing Ib phase clinical trials in 12 centers across China and the US, with completion expected in 2025[124] - APL-2301, a novel antibacterial drug for Acinetobacter baumannii infections, has been approved for Phase I clinical trials in Australia, focusing on safety, tolerability, and pharmacokinetics[128] - The company is developing APL-2302, a USP1 inhibitor, which has shown strong tumor-killing effects in preclinical studies and is planned for clinical trial applications in 2024[129][130][131] - APLD-2304, a portable blue-light bladder soft scope, is being developed to improve specificity and reduce false positives in bladder cancer diagnosis, with ongoing exploration of overseas commercialization opportunities[132][135] - AT-014, a high-selective growth factor receptor inhibitor, is being optimized using AI technology for treating bladder cancer and other advanced solid tumors[136] - AT-017, an epigenetic-related small molecule oral drug, is being developed for urogenital system tumors, with ongoing lead compound optimization using TAIDD platform[137] - AT-018 is a self-developed small molecule oral drug targeting cell cycle-related pathways, specifically for treating female-related cancers such as breast cancer, ovarian cancer, and endometrial cancer. The company utilizes the TAIDD platform for multi-conformation simulation and AI for compound optimization[138] - AT-020 is a next-generation ADC drug targeting new tumor antigens, with potential to address unmet clinical needs in bladder and breast cancers. Existing ADC drugs like Enfortumab Vedotin show an ORR of 50%-60% in advanced urothelial cancer, indicating significant room for improvement[139] - AT-021 is an ADC drug aimed at enhancing anti-tumor immunity by combining self-developed immune-boosting small molecules with targeted antibodies. It aims to improve efficacy and reduce side effects of current immunotherapies like CTLA-4 and PD-1 antibodies[140] - APL-1702, a photodynamic medical device combination product, is being developed for cervical high-grade squamous intraepithelial lesions, with plans to submit a Phase III clinical trial application to the FDA[146] - APL-1202, targeting MetAP2, is in development for untreated intermediate-risk NMIBC and as a neoadjuvant therapy for MIBC in combination with tislelizumab[146] - APL-1501, a second-generation APL-1202, is being developed for urological tumors, with clinical trials planned in Australia[146] - AT-014 and AT-020 are in development for urological tumors and various solid tumors, respectively, leveraging the TAIDD and ADC platforms[146] - APL-2302, targeting USP1, is being developed for ovarian and breast cancers, with global rights[146] Commercialization and Market Access - The company's oncology division has rapidly built a nearly 200-person commercialization team, aiming for over 100 million RMB in sales and internal break-even in 2024[39] - The company's HCCM platform has over 8,000 users, with more than 85% of registered doctors being from relevant fields, and nearly 1,500 interactions in the breast cancer field[40] - The company achieved sales of 9.2892 million yuan for its oncology products, including Dypate and Ouyoubi, by the end of the reporting period[63] - The company's oncology products, Dypate and Ouyoubi, achieved coverage in 80% of target cities by Q4 2023 and 100% by Q1 2024[68] - Dypate achieved sales in over 70% of target key hospitals within six months of launch, while Ouyoubi connected with major customers and benefited over 1,000 patients within three months of launch[68] - The company's market access team achieved 90% provincial bidding and dual-channel access for its oncology products[68] - The company established a Women's Health Division in early 2024 to focus on the commercialization of APL-1702 and expand its gynecological product pipeline[72] - The company is actively promoting the overseas development and collaboration opportunities for APL-1202/APL-1501 and exploring commercialization opportunities for a disposable blue-light cystoscope in the US clinic market[66] - The company is focusing on localizing production of imported drugs and devices to establish a reliable and agile supply chain while reducing costs[93] - The company is committed to providing optimal diagnostic and therapeutic solutions for bladder cancer, with a product portfolio covering NMIBC diagnosis, surgery, treatment, and follow-up[96] Environmental and Social Responsibility - The company invested 692,300 yuan in environmental protection during the reporting period[49] - The company consumed 1,921.52 tons of water and 908,100 kWh of electricity during the reporting period[51] - The company has implemented strict environmental management systems, including waste classification and hazardous waste disposal through qualified third-party companies[55][56] - The company released its first ESG report in 2023, integrating environmental, social, and governance factors into its strategic development to provide more decision-making information for investors[142] Shareholder and Employee Commitments - Employee stock ownership accounts for 4.28% of the total share capital[102] - Number of employees holding shares is 43, representing 10.91% of the total workforce[103] - Total employee shareholding is 2,437,600 shares[103] - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, and will not propose the company to repurchase these shares[155] - If the company's stock price remains below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for pre-listing shares will be automatically extended by 6 months[155] - In the event of major illegal activities leading to delisting, shareholders commit not to sell their shares from the date of the administrative penalty or judicial decision until the stock is delisted[155] - Shareholders who violate the share lock-up commitments must publicly explain the reasons and apologize to shareholders and the public, with any illegal gains from share sales to be returned to the company[155] - Certain shareholders, including Pan-Scientific, have committed to a 36-month lock-up period from the listing date, with similar penalties for violations[155] - Other shareholders, such as Taizhou Donghong and Taizhou Yahong, also have a 36-month lock-up period from the listing date, with additional commitments in case of delisting due to illegal activities[157] - Some shareholders, including Nanjing Ruike and QM139, have a lock-up period of 12 months from the listing date or 36 months from the completion of the industrial and commercial registration changes, whichever is longer[157] - Directors and senior management have a 12-month lock-up period from the listing date, with additional restrictions if the company is not profitable at the time of listing[160] - If the company is not profitable at the time of listing, directors and senior management cannot sell their pre-listing shares for 3 full fiscal years, and must comply with relevant regulations even after leaving the company[160] - In case of stock price falling below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for directors and senior management will be automatically extended by 6 months[160] - The company's core technical personnel are subject to a 12-month lock-up period from the date of listing, and a 6-month lock-up period after resignation, during which they cannot transfer or entrust others to manage their shares[166] - Core technical personnel can only transfer up to 25% of their pre-IPO shares annually for 4 years after the lock-up period expires[166] - The company's directors, supervisors, and senior management are restricted from transferring more than 25% of their total shares annually after the lock-up period[163] - If the company is not profitable at the time of listing, core technical personnel cannot reduce their pre-IPO shares for 3 full fiscal years[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is not profitable at the time of listing for 3 full fiscal years[163] - The company's directors, supervisors, and senior management cannot reduce their shares within 6 months after resignation[163] - The company's core technical personnel cannot reduce their shares within 6 months after resignation[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[163] - The company's core technical personnel cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[166] - The company's directors, supervisors, and senior management must publicly explain and apologize if they violate the share reduction commitments[163] - The company plans to reduce its shareholding by no more than 100% of its total shares within two years after the lock-up period expires, with the selling price not lower than the audited net asset value per share at the end of the previous fiscal year[173] - The company will initiate stock price stabilization measures if the stock price remains below the audited net asset value per share for 20 consecutive trading days within three years of listing[172] - The company will hold a board meeting within 10 days to pass a resolution on stock repurchase and submit it to the shareholders' meeting for approval if the stock price stabilization conditions are met[172] - The company will use its own funds for stock repurchase, with the repurchase price not exceeding the latest audited net asset value per share[172] - The company will repurchase shares through centralized bidding, tender offers, or other methods approved by securities regulators, with the annual repurchase amount not exceeding 50% of the net profit attributable to the parent company's shareholders in the most recent audited fiscal year[175] - If the company's stock price remains above the audited net asset value per share for three consecutive trading days, the repurchase plan will be terminated[175] - The controlling shareholder's share purchase plan will not exceed 20% of the after-tax cash dividends received from the company in the previous year, and the purchase price will not exceed the audited net asset value per share in the most recent fiscal year[175] - Directors and senior management will purchase shares within 90 days after the controlling shareholder's plan is completed, with the purchase amount not exceeding 20% of their after-tax compensation from the company in the previous year[178] - The company will cancel repurchased shares within 10 days after the completion or termination of the repurchase plan and proceed with the capital reduction process[175] - The company will extend the period for six months after expiration and return the after-tax cash dividends received from the company in the most recent fiscal year. If not returned on time, the company may deduct from future cash dividends until the cumulative deduction reaches the total after-tax cash dividends received in the most recent fiscal year[181] - If directors or senior management fail to fulfill their commitments to stabilize stock prices within three years of listing, they must publicly explain the reasons, apologize, and propose supplementary or alternative commitments. Additionally, 20% of their monthly after-tax salary will be deducted until the cumulative deduction reaches 20% of their after-tax salary from the most recent fiscal year[181] - In case of false statements or major omissions in the prospectus that significantly affect the company's compliance with legal issuance conditions, the company will repurchase all newly issued shares. The repurchase price will be determined according to regulatory documents and will not be lower than the market price at the time of repurchase[181] - If the company violates